1Chobannian AV,Bakris GL,Black HR,et al.The seventh report of the joint national committee on prevention,detection,evaluation,and treatment of high blood pressure[].The Journal of The American Medical Association.2003
2AziziM,Menard J,Bissery A,et al.Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin ll-renin feedback interruption[].Journal of the American Society of Nephrology.2004
4Gradman AH,Schimieder RE,Lins RL,et al.Aliskiren,a novel orally effective renin inhibitor,provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients[].Circulation.2005
5Jeffrey AB,Maria PC,Ligaya MS,et al.Dual metalloprotease inhibitors 6 incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors[].Journal of Medicinal Chemistry.1996
6Sica DA.Combination angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy:its role in clinical practice[].Journal of Clinical Hypertension.2003
7Krum H,Gilbert RE.Novel therapies blocking the renin-angiotensin- aldosterone system in the management of hypertension and related disorders[].Journal of Hypertension.2007
8Bralet J,Schwarts JC.Vasopeptidase inhibitors:an emerging clasee of cardiovascular drugs[].Trends in Pharmacological Sciences.2001
9Nathisuwan S,Talber RL.A review of vasopeptidase inhibitors:a new modality in the treatment of hypertension and chronic heart failure[].Pharmacotherapy.2002
10Rocha R,Stier CT,Kifor I,et al.Aldosterone:a mediator of myocardial necrosis and renal arteriopathy[].The Journal of Endocrinology.2000
